Philip Bonomi to Patient Selection
This is a "connection" page, showing publications Philip Bonomi has written about Patient Selection.
Connection Strength
0.742
-
Selecting patients for treatment with epidermal growth factor tyrosine kinase inhibitors. Clin Cancer Res. 2007 Aug 01; 13(15 Pt 2):s4606-12.
Score: 0.271
-
Expanding Access to Lung Cancer Clinical Trials by Reducing the Use of Restrictive Exclusion Criteria: Perspectives of a Multistakeholder Working Group. Clin Lung Cancer. 2020 07; 21(4):295-307.
Score: 0.162
-
Implications of key trials in advanced nonsmall cell lung cancer. Cancer. 2010 Mar 01; 116(5):1155-64.
Score: 0.081
-
Phase III trial comparing paclitaxel poliglumex vs docetaxel in the second-line treatment of non-small-cell lung cancer. Br J Cancer. 2008 May 20; 98(10):1608-13.
Score: 0.072
-
Therapeutic advances in second-line treatment of advanced non-small-cell lung cancer. Clin Lung Cancer. 2004 Nov; 6(3):154-61.
Score: 0.056
-
Relationship between circulating tumor-associated autoantibodies and clinical outcomes in advanced-stage NSCLC patients receiving PD-1/-L1 directed immune checkpoint inhibition. J Immunol Methods. 2021 03; 490:112956.
Score: 0.043
-
The role of positron emission tomography in selecting patients with metastatic cancer for adrenalectomy. Am Surg. 2000 May; 66(5):432-6; discussion 436-7.
Score: 0.041
-
PIONEER: a phase III randomized trial of paclitaxel poliglumex versus paclitaxel in chemotherapy-naive women with advanced-stage non-small-cell lung cancer and performance status of 2. Clin Lung Cancer. 2006 May; 7(6):417-9.
Score: 0.016